Wells Fargo & Company Arbutus Biopharma Corp Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Wells Fargo & Company holds 48,831 shares of ABUS stock, worth $171,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,831

Previous 48,137 1.44%

Holding current value

$171,885

Previous $148,000 26.35%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$3.12 - $4.56 $2,165 - $3,164	694 Added 1.44%	48,831 $187,000
Q2 2024 Aug 13, 2024	BUY	$2.52 - $3.63 $13,222 - $19,046	5,247 Added 12.23%	48,137 $148,000
Q1 2024 May 10, 2024	BUY	$2.26 - $2.92 $12,032 - $15,546	5,324 Added 14.17%	42,890 $110,000
Q4 2023 Feb 09, 2024	BUY	$1.69 - $2.54 $9,224 - $13,863	5,458 Added 17.0%	37,566 $93,000
Q3 2023 Nov 13, 2023	SELL	$1.9 - $2.27 $43,945 - $52,502	-23,129 Reduced 41.87%	32,108 $65,000
Q2 2023 Aug 15, 2023	BUY	$2.24 - $3.06 $61,333 - $83,785	27,381 Added 98.29%	55,237 $127,000
Q1 2023 May 12, 2023	BUY	$2.23 - $3.1 $41,823 - $58,140	18,755 Added 206.08%	27,856 $84,000
Q4 2022 Feb 13, 2023	BUY	$1.91 - $2.85 $2,251 - $3,360	1,179 Added 14.88%	9,101 $21,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $565 - $866	301 Added 3.95%	7,922 $14,000
Q2 2022 Aug 12, 2022	SELL	$1.98 - $3.17 $172,626 - $276,376	-87,185 Reduced 91.96%	7,621 $20,000
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $55,381 - $91,082	-22,885 Reduced 19.44%	94,806 $282,000
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $953,933 - $1.41 Million	-306,731 Reduced 72.27%	117,691 $458,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $1.11 Million - $1.94 Million	420,496 Added 10710.55%	424,422 $1.82 Million
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $1,875 - $2,632	-750 Reduced 16.04%	3,926 $12,000
Q1 2021 May 13, 2021	SELL	$3.14 - $4.84 $113 - $174	-36 Reduced 0.76%	4,676 $15,000
Q4 2020 Feb 09, 2021	SELL	$2.76 - $4.97 $1,722 - $3,101	-624 Reduced 11.69%	4,712 $17,000
Q3 2020 Nov 05, 2020	BUY	$1.75 - $6.2 $4,263 - $15,103	2,436 Added 84.0%	5,336 $16,000
Q1 2020 May 14, 2020	BUY	$1.01 - $3.42 $2,929 - $9,918	2,900 New	2,900 $3,000

Others Institutions Holding ABUS

# of Institutions

156

Shares Held

99.6M

Call Options Held

2.31M

Put Options Held

525K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $528M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Arbutus Biopharma Corp Transaction History